October 25, 2019

TesoRx Subsidiary LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study More...

September 16, 2019

TesoRx Subsidiary LIPAC Oncology and Huons Co. Announce Exclusive Licensing Agreement for TBC-1002 in Korea More...

December 1, 2017 

TesoRx Pharma And ASKA Pharmaceutical Expand Territory And Scope Of Partnering Agreement For TesoRx's Oral Testosterone Product - ASKA makes Equity Investment into TesoRx. More...

November 30, 2017 

TesoRx Announces Commencement of Enrollment of a Clinical Trial Evaluating Novel Oral Testosterone Replacement Therapy in Patients with Hypogonadism. More...

April 27, 2017  

ASKA and TesoRx Announce TSX-011 (Oral Testosterone) Proceeding to Human Studies Following Successful PK Study Results. More...

January 9, 2017

TesoRx Announces Creation of LIPAC Oncology and Advancement of Oncology Pipeline. More...

ASKA and TesoRx Announce Partnership to Develop Oral Testosterone for the Japanese Market. More...  

June 8, 2016

FDA grants orphan designation for TesoRx's unmodified Testosterone treatment for Constitutional Delay in Growth in Puberty (CDGP) for boys. More...

April 3, 2015

Official Opening of TesoRx Centre of Excellence at Western University. More...

October 20, 2014

TesoRx and Aspen Group Conclude Investment and Licensing Agreement. More...

August 5, 2014

TesoRx Closes $10M in Funding, Secures Key Patent and Hires Renowned Urologist as Chief Medical Officer. More...

May 16, 2014

TesoRx Announces Participation at the American Urological Association (AUA) 2014 Conference. More...

August 28, 2013

TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug. More...

December 31, 2010

TesoRx closes Series A funding round. More...

July 30, 2010

TesoRx licenses Testosterone Replacement Therapy technology. More...

April 30, 2010

Well-known pharma personality forms TesoRx. More...